Table 1.
Studies included in the analysis (n = 4685)
| Study | Intervention (mg/day) | n | Change in LDL-C (%) | Change in non- HDL-C (%) | Change in ApoB (%) | Change in coronary plaque volume (%) | Months of treatment exposure |
|---|---|---|---|---|---|---|---|
| REVERSAL10 | Atorvastatin 80 | 253 | -46.3 | -42.9 | -39.1 | -0.4 | 18 |
| REVERSAL10 | Pravastatin 40 | 249 | -25.2 | -24.7 | -22 | 2.7 | 18 |
| ESTABLISH11 | Atorvastatin 20 | 35 | -41.7 | -35.4 | -27.9 | -13.1 | 6 |
| ESTABLISH11 | Control | 35 | -0.7 | -1.9 | 2.4 | 8.7 | 6 |
| JAPAN-ACS12 | Pitavastatin 4 | 125 | -36.2 | -30.5 | -27.6 | -16.9 | 8-12 |
| JAPAN-ACS12 | Atorvastatin 20 | 127 | -35.8 | -30.1 | -27.6 | -18.1 | 8-12 |
| SATURN13 | Atorvastatin 80 | 519 | -41.5 | -35.9 | -28.4 | -4.0 | 26 |
| SATURN13 | Rosuvastatin 40 | 520 | -47.8 | -40.2 | -30.9 | -5.8 | 26 |
| Hong et al.14 | Rosuvastatin 20 | 65 | -49 | -44 | -36 | -2.7 | 11 |
| Hong et al.14 | Atorvastatin 40 | 63 | -40 | -35.4 | -34 | -1.9 | 11 |
| COSMOS15 | Rosuvastatin 2,5-20 | 215 | -38.6 | -36.7 | -31.3 | -5.1 | 19 |
| ASTEROID6 | Rosuvastatin 40 | 346 | -53.2 | -47.2 | -41.5 | -6.7 | 24 |
| ARTMAP16 | Atorvastatin 10-20 | 143 | -47 | -43.4 | - | -3.9 | 6 |
| ARTMAP16 | Rosuvastatin 20 | 128 | -49 | -45.9 | - | -7.4 | 6 |
| GAIN17 | Atorvastatin 20-80 | 65 | -42 | -41 | - | 2.5 | 12 |
| GAIN17 | Usual care | 66 | -16 | -15.9 | - | 11.8 | 12 |
| Kawasaki et al.18 | Control | 17 | -1.9 | -1.1 | - | 0 | 6 |
| Kawasaki et al.18 | Pravastatin 20 | 17 | -31.5 | -28.6 | - | -0.9 | 6 |
| Kawasaki et al.18 | Atorvastatin 20 | 18 | -38.7 | -39.2 | - | -2.4 | 6 |
| Jensen et al.19 | Simvastatin 40 | 40 | -46.3 | -42.8 | - | -6.3 | 3-12 |
| Jensen et al.19 | Diet | 40 | -2.4 | -2.1 | - | -0.4 | 3-12 |
| Han et al.20 | Rosuvastatin 20 | 21 | -54.2 | -44.6 | - | -8.5 | 9-12 |
| Han et al.20 | Rosuvastatin 20/Ramipril 10 | 19 | -47.2 | -43.6 | - | -11.6 | 9-12 |
| STRADIVARIUS21 | Placebo | 341 | -3.2 | -3.8 | 0.5 | 18 | |
| A-PLUS22 | Placebo | 154 | 1.7 | 1.9 | -4 | -1.2 | 24 |
| AQUARIUS23 | Placebo | 233 | 5.6 | 4.4 | - | -1.1 | 26 |
| Tani et al.24 | Pravastatin 10-20 | 84 | -11.3 | -12.1 | -6.4 | -12.6 | 6 |
| Nozue et al.25 | Pitavastatin 4 | 58 | -41 | -37.9 | -33 | -2.2 | 8 |
| Nozue et al.25 | Pravastatin 20 | 61 | -29 | -26.4 | -25.2 | -1.4 | 8 |
| Hirayama et al.26 | Atorvastatin 10-20 | 20 | -36.3 | -36.4 | -28.4 | -18.9 | 20 |
| HEAVEN 27 | Atorvastatin 80/Ezetimibe 10 | 42 | -28.6 | -32.3 | -5.8 | -2.9 | 12 |
| HEAVEN27 | Standard treatment | 47 | -1.9 | -9.2 | 7.4 | 0.7 | 12 |
| CART-228 | Placebo | 111 | -6.9 | -8.4 | - | -0.3 | 12 |
| ENCORE II29 | Placebo | 112 | -11.8 | -9.8 | - | -0.3 | 18-24 |
| Nasu et al.30 | Fluvastatin 40 | 40 | -32.3 | -32.8 | -27 | -8.3 | 12 |
| Nasu et al.30 | Control | 39 | 2.2 | 4 | 2.3 | 2.5 | 12 |
| Yamada et al.31 | Atorvastatin 10-20 | 26 | -32.5 | -29.8 | -27.6 | -1.9 | 12 |
| Yamada et al.31 | Usual care | 32 | 0 | -1.6 | -2.2 | 11.5 | 12 |
| Tani et al.32 | Pravastatin 10-20 | 52 | -14 | -17.9 | - | -14 | 6 |
| Tani et al.32 | Control | 23 | 3.6 | 2.5 | - | 1.1 | 6 |
| Yokoyama et al.33 | Atorvastatin 10 | 29 | -34 | -30.5 | - | -5.6 | 6 |
| Yokoyama et al.33 | Control | 30 | -4.4 | -5.2 | - | -3.5 | 6 |
| Nakayama et al.34 | Control | 25 | -7.1 | -4.6 | - | 2.8 | 6 |